DOCSLIB.ORG

Pharmaderm-Catalogue-En.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaderm-Catalogue-En.Pdf Your health is our priority Pharmaderm laboratories, founded in 1986, are among the first Tunisian pharmaceutical laboratories. Wealth of an experience of 25 years in the pharmaceutical field, Pharmaderm laboratories have developed expertise in the development and manufacture of complexes semi-solid and liquid forms. With an active and dynamic R&D Department, Pharmaderm laboratories work to expand their lines but also to extend their scope to new therapeutic fields. • Allergy, antihistaminics • Analgesics, antipyretics • Dermatology: . Local antiseptics . Local anti herpes . Local antifungals . Skin protectors . Corticosteroids: o Alone o Related • Gynecology: Local antiseptics • Infectious disease: Antivirals • Pneumology: . Mucolytics . Decongestants • Rheumatology: Topical anti-inflammatory • Stomatology: Local antiseptics Allergy, Allergamine Dexchlorpheniramine maleate 0.01% Syrup Bt/125ml 5 Antihistaminics Methyl Salicylate, Camphor, Turpentine Essence, Pneumology, Baume cal mol Dermic cream T/60g 5 Levomenthol, Eucalyptol Decongestants Salicylic acid 3 % Dermic ointment T/15g Betamethasone 0.05 % (dipropionate) Dermatology, Bétasalic 2 Related Salicylic acid 2% Dermic lotion Bt/30g Corticosteroids Betamethasone 0.05 % (dipropionate) Dermic solution Dermatology, 3 Bt/500ml, 125ml, 20 ml Local antiseptics Bétavidine PVP Iodine 10% Gynecological solution Gynecology, 3 Bt/500ml, 125ml, 20 ml Local antiseptics Methyl Salicylate, Turpentine,Essence Pneumology, Calyptine Dermic cream T/40g 5 Levomenthol, Eucalyptol Decongestants Carbocisteine 2% Children Syrup Bt/125ml 3 Pneumology, Carbostine Mucolytics Carbocisteine 5% Adult Syrup Bt/200ml 3 Methyl Salicylate, Camphor, Turpentine Essence , Pneumology, Chéfix Liniment Bt/5ml 5 Levomenthol, Eucalyptol Decongestants Infectious disease, Acyclovir 400mg/5 ml Oral suspension Bt/125ml 2 Antivirals Ciclovirax Dermatology, Acyclovir 5% Dermic cream T/5g 2 Local anti herpes Dermatology, Triamcinolone acetonide 0.1% Cinoderm Dermic ointment T/10g 5 Related Neomycin sulfate 0.5% Corticosteroids 0.01% Dermic ointment T/50g, 20g 5 and3 Dermatology, 0.01% Dermic lotion Bt/30 ml 3 Corticosteroids Fluocinonide 0.025% Dermic Gel T/30g 3 0.05% Dermic cream T/15g 3 Cortéma Alone 0.05% Dermic ointment T/15g 4 Fluocinonide 0.05% Dermic ointment T/15g 5 Related Neomycin sulfate 0.5% Dermic ointment T/15g 3 Dermatology, Betamethasone 0.05% (dipropionate) Dermic cream T/15g 3 Corticosteroids Dimétasone Dermic lotion Bt/30g 2 Alone Betamethasone 0.05% (dipropionate) Dermic ointment T/15g 3 Related Neomycin sulfate: 0.535% Mowthwash Stomatology, Héxident Chlorhexidine 0.12% 4 Bt/125ml Local antiseptics Dermic milk Bt/30ml Dermatology, Mycoderm Econazole nitrate 1% 3 Dermic cream T/30g Local antifungals Dermatology, Mytoplastine Zinc oxyde 35% Dermic ointment T/50g , T/20g 5 and 3 Skin protectors Triamcinolone acetonide 0.1% Dermatology, Néostyne Neomycin sulfate 0.365% Dermic ointment T/10g 3 Related Nystatine 2.27% Corticosteroids Rheumatology: Nifluderm Niflumic acid 3% Dermic cream T/60g 5 Topical anti- inflammatory Paracétyl Analgesics, Acetaminophen 3% Oral solution Bt/90ml 3 pediatric antipyretics Dermic cream T/10g Dermatology, Psoriacort Clobetasol propionate 0.05% Dermic ointment T/10g 2 Corticosteroids Hair gel Bt/20g Alone Dermatology, Dermic cream T/10g Betamethasone 0.1% (valérate) 3 Corticosteroids Dermic ointment T/10g Alone Valécort Betamethasone 0.1%( valérate) Dermic cream T/10g 3 Related Neomycin sulfate 0.5% Dermic ointment T/10g Syrup (Bottle 125ml) Therapeutic class: Allergy, antihistaminics Indications For adults and children over 2 years Symptomatic treatment of various allergic manifestations: •Rhinitis (seasonal and perennial) •Conjunctivitis •Urticaria Stable for 5 years API Composition: Dexchlorpheniramine maleate: 0.01% Dermic cream (Tube 60g) Therapeutic class: Pneumology, Decongestants Indications For adults and older Children: •Treatment of external bronchitis •Rheumatism •Rheumatic or traumatic neuralgia •Cramps •Sprains, dislocations •Muscle strains Stable for 5 years API Composition: Methyl salicylate : 4.5% Camphor: 3% Turpentine Essence : 3% Levomenthol: 2% Eucalyptol: 2% Dermic ointment (Tube 15g) Therapeutic class: Dermatology, Related corticosteroids Indications Stable for 2 years Dermatosis with keratotic or squamous component: •Indications where local corticotherapy is the best treatment: lichenification •Indications where the corticotherapy is one of the usual treatments: psoriasis, lichen, seborrhoeic dermatitis with the exception of the face. API Composition: Salicylic acid: 3 % Betamethasone : 0.05 % (dipropionate) Dermic lotion (Bottle 30 g) Therapeutic class: Dermatology, Related corticosteroids Indications Suitable for the treatment of diseases of the scalp, hairy areas and folds. Dermatosis with keratotic or squamous component: •Indications where local corticotherapy is the best treatment: lichenification •Indications where the corticotherapy is one of the usual treatments: psoriasis, lichen, seborrhoeic dermatitis with the exception of the face. Stable for 2 years API Composition: Salicylic acid: 2 % Betamethasone : 0.05 % (dipropionate) (Bottle 500ml, 125ml and 20ml) Therapeutic class: Dermatology, local antiseptics Stable for 3 years Indications • Antisepsis of wounds or burns superficial and not extensive. • Adjunctive treatment of diseases of the skin and mucous originally bacterial or may become secondarily infected. • Antisepsis of the skin of the operative field. API Composition: PVP iodine: 10% (Bottle 500ml, 125ml and 20ml) Therapeutic class: Gynecology, local antiseptics Stable for 3 years Indications Treatment of local vaginal infections caused by sensitive bacteria. API Composition: PVP iodine: 10% Dermic cream (Tube 40g) Therapeutic class: Pneumology, Decongestants Indications •Mild Bronchitis •Colds •End of bronchopneumonia with irritative troublesome cough Stable for 5 years API Composition: Methyl salicylate :0.4% Levomenthol: 0.4% Turpentine Essence :1.5% Eucalyptol: 2% Children syrup (Bottle 125 ml) Therapeutic class: Pneumology, Mucolytics Indications For children over 2 years: Treatment of disorders of the bronchial secretion, especially during the acute bronchial disorders: acute bronchitis and acute episode of chronic obstructive pulmonary disease. Stable for 3 years API Composition: Carbocisteine :2% Adult syrup (Bottle 200 ml) Therapeutic class: Pneumology, Mucolytics Indications Treatment for recent respiratory difficulties with sputum. Stable for 3 years API Composition: Carbocisteine: 5% Liniment (Bottle 5 ml) Therapeutic class: Pneumology, Decongestants Indications •Balsamic •Fighting cold attacks •Decongestant Stable for 5 years API Composition: Methyl salicylate : 18% Levomenthol: 18% Eucalyptol: 18% Camphor: 8% Turpentine Essence : 4% Oral suspension (Bottle 125 ml) Therapeutic class: Infectious disease, Antivirals Indications 1 / Subject immunocompromised: Prevention of HSV infection. 2 / Subject immunocompetent: a / skin or mucosal infections: • Treatment of severe cutaneous or mucosal herpes infections (primary infections), especially genital herpes and acute herpetic gingivostomatitis. • Treatment of recurrent genital herpes. • Prevention of HSV infection, in patients with at least 6 recurrences per year. b / eye infections: • Prevention of recurrent ocular HSV infections: Epithelial keratitis after three recurrences per year or in case of known trigger keratitis; Stromal keratitis and kerato-uveitis after two recurrences per year ; In case of eye surgery. • Treatment of keratitis and kerato-uveitis HSV. Stable for 2 years API Composition: Acyclovir : 400mg/5ml Dermic cream (Tube 5 g) Therapeutic class: Dermatology, Local anti herpes Stable for 2 years Indications The indications arise from the activity of acyclovir on herpes simplex virus types 1 and 2: •Genital herpes: treatment of primary infection and any subsequent recurrences •Labialis herpes: Ciclovirax cream helps accelerate healing during recurrences API Composition: Acyclovir : 5% Dermic ointment (Tube 10 g) Therapeutic class: Dermatology, Related Corticosteroids Indications Any non-exudative dermatitis justifiable of topical steroids, with superinfection during the first 8 days of treatment, including: atopic eczema in early treatment, infected contact dermatitis, infected nummular eczema . -Proposed in: essential anogenital pruritus, infected neurodermatitis, infected seborrheic dermatitis, infected peri-ulcerative dermatitis for a period not exceeding 8 days. Stable for 5 years API Composition: Triamcinolone acetonide: 0.1% Neomycin sulfate: 0.5% Dermic ointment (Tube 50 g and 20 g) Therapeutic class: Dermatology, Corticosteroids only Indications For dry and scaly lesions: •Psoriasis •Contact or atopic eczemas •Primary irritation dermatitis. 50g :Stable 5 years 20g :Stable 3 years API Composition: Fluocinonide: 0.01% Hair and body lotion (Bottle 30 ml) Therapeutic class: Dermatology, Corticosteroids only Indications •Psoriasis •Contact or atopic eczemas •Primary irritation dermatitis of scalp Stable for 3 years API Composition: Fluocinonide: 0.01% Dermic gel (Tube 30 g) Therapeutic class: Dermatology, Corticosteroids only Indications Lichen, lichenification, non-parasitic prurigo, dyshidrose, genital sclerosus lichen, annulare granuloma, discoid lupus erythematosus, amicrobial palmoplantar pustulosis, stasis dermatitis, seborrheic dermatitis except the face, symptomatic treatment of pruritus. Stable for 3 years API Composition: Fluocinonide: 0.025%
Load more

Recommended publications
  • Vesicular and Ulcerative Dermatopathy Resembling Superficial Necrolytic Dermatitis in Captive Black Rhinoceroses (Diceros Bicornis)
    Vet Path01 353 1-42 (1998) Vesicular and Ulcerative Dermatopathy Resembling Superficial Necrolytic Dermatitis in Captive Black Rhinoceroses (Diceros bicornis) L. MUNSON, J. W. KOEHLER, J. E. WILKINSON, AND R. E. MILLER Department of Pathology, College of Veterinary Medicine, University of Tennessee,Knoxville, TN (LM, JWK, JEW); and Department of Animal Health, St. Louis Zoological Park, St. Louis, MO (REM) Abstract. The histopathology, clinical presentation, and epidemiology of a cutaneous and oral mucosal disease affecting 40 black rhinoceroses (Diceros bicomis) at 21 zoological parks (50% of the captive US population) were investigated. Twenty-seven biopsies were examined from recent lesions, and clinical infor- mation was available from 127 episodes.The cutaneous lesions began as plaques that progressedto vesicles, bullae, or ulcers. Lesions waxed and waned in individual cases.Lesions were predominantly bilaterally sym- metrical, affecting pressurepoints, coronary bands, tips of the ears and tail, and along the lateral body wall and dorsum. Oral lesions were first noticed as ulcers and were present on the lateral margins of the tongue, palate, and mucocutaneousjunctions of the lips. All recent lesions had similar histopathologic findings of prominent acanthosis,hydropic degenerationof keratinocytes in the stratum spinosum,spongiosis, intraepithelial vesicles, and parakeratosiswithout dermal inflammation. Chronic lesions were ulcerated. No pathogens were identified by culture or electron microscopy. Most episodescoincided with stressevents
    [Show full text]
  • PLENARY SESSION ABSTRACTS Theme: IMMUNITY and AUTOIMMUNITY
    PLENARY SESSION ABSTRACTS Theme: IMMUNITY AND AUTOIMMUNITY State-of-the-Art Address Supporting Review What’s new in autoimmune blistering diseases? Epithelial, immune cell and microbial cross- D. F. MURRELL talk in homeostasis and atopic dermatitis Department of Dermatology, St George Hospital, and T. KOBAYASHI UNSW Faculty of Medicine, Sydney, New South Wales, Laboratory for Innate Immune Systems, RIKEN Center Australia for Integrative Medical Sciences (IMS), Yokohama, There are several blistering diseases which occur natu- Japan rally in other species as well as in humans; for example, Skin is a complex and dynamic ecosystem, wherein the pemphigus occurs naturally in dogs and horses and the epithelial cells, immune cells and microbiota engage in inherited blistering disease, epidermolysis bullosa, also active dialogues and maintain barrier integrity and occurs in dogs. Several new validated scoring systems functional immunity. Alterations of the peaceful coexis- to measure the severity of autoimmune blistering dis- tence with the resident microbiota, referred to as dys- ease (AIBD) have been developed which assist in biosis, lead to dysregulation of host immunity. It has demonstrating efficacy of new treatments, such as the been long debated whether the dysbiosis in the skin of Pemphigus Disease Area Index (PDAI) for pemphigus atopic dermatitis is merely a consequence of chronic and Bullous Pemphigoid Disease Area Index (BPDAI) skin inflammation or whether it is actively involved in for pemphigoid. Pemphigus is due to autoantibodies to driving skin inflammation. Microbiome analysis by 16S desmogleins 1 and 3 in human pemphigus foliaceus and rRNA sequencing in humans and dogs with atopic der- vulgaris and desmocollin1 in canine pemphigus foli- matitis showed the shifts in microbial diversity repre- aceus, generated by the late onset activation of the sented by increased proportion of Staphylococcus spp.
    [Show full text]
  • A Retrospective Study of Idiopathic Ulcerative Dermatitis in Mice with a C57BL/6 Background
    Journal of the American Association for Laboratory Animal Science Vol 45, No 6 Copyright 2006 November 2006 by the American Association for Laboratory Animal Science Pages 8-12 Reports A Retrospective Study of Idiopathic Ulcerative Dermatitis in Mice with a C57BL/6 Background Robin J Kastenmayer,* Michele A Fain, and Kathy A Perdue Idiopathic ulcerative dermatitis is a well-recognized disease in C57BL mice and related strains. This disease manifests as a pruritic dermatitis with resulting self-mutilation, dermal ulceration, necrosis, and fibrosis. Ulcerative dermatitis has the ability to confound ongoing research by causing systemic pathologic changes, such as lymphadenopathy and splenomegaly. Although various treatments have been described, none has been curative consistently; therefore, minimizing negative effects on research through prevention of disease is ideal. To identify etiologic factors, we conducted a 2-y retrospective study of 1352 mice with a C57BL/6 genetic background; these mice demonstrated an overall prevalence of 4.1% and a seasonal effect with a peak incidence during midsummer. Corroborating previous studies, our study revealed a disease predilection for female mice. In contrast to prior reports, the disease prevalence was greatest in 10- to 16-mo-old mice. In addition, mice with a C57BL/6 background that were deficient in the gene for inducible nitric oxide synthase had a 50% disease incidence, suggesting a potential animal model for further characterizing the pathogenesis, prevention, and treatment of ulcerative dermatitis. Abbreviations: iNOS, inducible nitric oxide synthase; UD, ulcerative dermatitis Idiopathic ulcerative dermatitis (UD) with pruritus is a Allentown, NJ) with corncob bedding (Harlan Teklad, Madison, common condition in C57BL mice, especially C57BL/6J mice.
    [Show full text]
  • PRODUCT MONOGRAPH Prerbitux®
    PRODUCT MONOGRAPH PrERBITUX® (cetuximab) Intravenous Injection, 2 mg cetuximab / mL 50 mL and 100 mL vials Antineoplastic Manufactured by ImClone LLC Date of Authorization: Branchburg, NJ, USA January 10, 2018 Distributed by Date of Revision: Eli Lilly Canada Inc. Exchange Tower August 13, 2020 130 King Street West, Suite 900 P.O. Box 73 Toronto, Ontario M5X 1B1 1-888-545-5972 www.lilly.ca Control No.: 211842 Page 1 of 77 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.................................................................................................................3 SUMMARY PRODUCT INFORMATION ...................................................................................................................................3 INDICATIONS AND CLINICAL USE..........................................................................................................................................3 CONTRAINDICATIONS................................................................................................................................................................4 WARNINGS AND PRECAUTIONS.............................................................................................................................................4 ADVERSE REACTIONS.............................................................................................................................................................. 10 DRUG INTERACTIONS.............................................................................................................................................................
    [Show full text]
  • Ulcerative Dermatitis in C57BL/6 Mice
    AN ABSTRACT OF THE THESIS OF Jennifer L. Sargent for the degree of Master of Science in Veterinary Science presented on June 2, 2015 Title: Ulcerative Dermatitis in C57BL/6 Mice Abstract approved: ______________________________________________________________________________ Helen E. Diggs Abstract Ulcerative dermatitis (UD) is a common condition in C57BL/6 mice that is poorly understood and challenging to treat. Inconsistently there have been reports of an increased incidence of the disease in female mice, mice exposed to certain diets, mice of advanced age, and in several seasons. These inconsistencies indicated a need for a systematic review to better assess the evidence for commonly cited UD risk factors and treatments. The aims for the systematic review were to assess the quality of evidence for both: 1) commonly cited risk factors for UD, specifically sex, age, season, and diet; and 2) reported UD treatments. A search of three electronic databases was performed and articles were evaluated using previously published criteria for assessing methodological quality. Dietary factors, particularly caloric restriction, appear to have an effect on UD risk. Female sex was associated with an increased risk of UD in some studies, particularly diet studies, but not in others. Also, UD was seen most commonly in mice between 14 and 24 months of age in the studies reviewed. The role of season was not assessed in any of the articles that met the inclusion criteria. Of the three publications that evaluated UD treatments only one had an untreated or alternative therapy control. Further research is needed to explore epidemiologic aspects of UD and to compare treatment options.
    [Show full text]
  • Die Prinzipien Der Chirurgischen Therapie Beim Fortgeschrittenen
    Aus der Chirurgischen Klinik und Poliklinik - Innenstadt, der Ludwig-Maximilian- Universität-München Direktor: Prof. Dr. med. Wolf Mutschler Die Prinzipien der chirurgischen Therapie beim fortgeschrittenen Pyoderma gangränosum Dissertation zum Erwerb des Doktorgrades der Medizin an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München vorgelegt von Christoph Hendrik Volkering aus Groß-Gerau 2008 Mit Genehmigung der Medizinischen Fakultät der Universität München Berichterstatter: Prof. Dr. Sigurd Keßler Mitberichterstatter: Prof. Dr. Hans C. Korting Priv. Doz. Dr. Martin K. Angele Dekan: Prof. Dr. med. Dr. h.c. Maximilian Reiser, FACR Tag der mündlichen Prüfung: 20.11.2008 - 2 - INHALT 1. Einleitung: ........................................................................................................... - 6 - 1.1. Das Pyoderma gangränosum: ..................................................................... - 6 - 1.1.1. Geschichte: ......................................................................................... - 6 - 1.1.2. Inzidenz: ............................................................................................. - 6 - 1.1.3. Assoziierte Erkrankungen: .................................................................. - 7 - 1.1.4. Typen des Pyoderma gangränosum: .................................................. - 9 - 1.1.5. Histopathologie: ................................................................................ - 12 - 1.1.6. Pathogenese: ...................................................................................
    [Show full text]
  • Aminoglycoside Allergic Reactions
    pharmacy Review Aminoglycoside Allergic Reactions Lindsey M. Childs-Kean 1,* , Kristy M. Shaeer 2, Sheeba Varghese Gupta 3 and Jonathan C. Cho 4 1 Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL 32610, USA 2 Department of Pharmacotherapeutics and Clinical Research, University of South Florida College of Pharmacy, Tampa, FL 33612, USA 3 Department of Pharmaceutical Sciences, University of South Florida College of Pharmacy, Tampa, FL 33612, USA 4 Department of Clinical Sciences, Ben and Maytee Fisch College of Pharmacy, The University of Texas at Tyler, Tyler, TX 75799, USA * Correspondence: [email protected]fl.edu Received: 13 July 2019; Accepted: 25 August 2019; Published: 29 August 2019 Abstract: Aminoglycosides are antimicrobial agents that are primarily used for infections caused by Gram-negative pathogens. The purpose of this article is to review the allergic reactions reported in the published literature to aminoglycoside antibiotics. A thorough PubMed search was conducted and excluded non-allergic adverse reactions to aminoglycosides. Allergic reactions to aminoglycosides occur infrequently, but can include cutaneous reactions as well as systemic reactions, including anaphylaxis. Of the evaluated aminoglycosides, gentamicin had the most reported allergic reactions, including the most reports of anaphylaxis, followed by tobramycin, and then amikacin. Most reports of allergic reactions occurred in patients who had a prior exposure to some dosage form of an aminoglycoside. Cross-reactivity among aminoglycosides is common and occurs due to the similarities in their chemical structures. Desensitization protocols to tobramycin have been described in the literature. Keywords: aminoglycosides; allergy; hypersensitivity; gentamicin; tobramycin; amikacin 1. Introduction Antibiotics are one of the most common causes of life-threatening medication allergies [1].
    [Show full text]
  • Differential Diagnosis in Dermatology
    Differential Diagnosis in Dermatology ZohrehTehranchi Dermatologist COMMON ACNE AND CYSTIC ACNE Rosacea Rosacea PERIORAL DERMATITIS ECZEMA/DERMATITIS Chronic irritant dermatitis Dyshidrotic eczematous dermatitis Childood atopic dermatitis Autosensitization dermatitis (“id” reaction): dermatophytid Seborrheic dermatitis PSORIASIS VULGARIS Pemphigus vulgaris BULLOUS PEMPHIGOID (BP) Pityriasis rosea small-plaque parapsoriasis Large-plaque parapsoriasis (parapsoriasis en plaques) LICHEN PLANUS (LP) GRANULOMA ANNULARE (GA) Erythema multiforme ERYTHEMA NODOSUM Actinic keratoses Bowen disease (Squamous cell carcinoma in situ) Bowen disease and invasive SCC Squamous cell carcinoma: invasive on the lip Squamous cell carcinoma, well differentiated Squamous cell carcinoma, undifferentiated Squamous cell carcinoma, advanced, well differentiated, on the hand Keratoacanthoma showing different stages of evolution BASAL CELL CARCINOMA (BCC) Basal cell carcinoma, ulcerated: Rodent ulcer A large rodent ulcer in the nuchal and Bas cell calarcinoma: sclerosing type retroauricular area extending to the temple Basal cell carcinoma, sclerosing, nodular, Superficial basal cell carcinoma: solitary lesion and multiple lesions Superficial basal cell carcinoma, invasive Basal cell carcinoma, pigmented Dysplastic nevi Superficial spreading melanoma: arising within a dysplastic nevus Congenital nevomelanocytic nevus Melanoma: arising in small CNMN Melanoma in situ: lentigo maligna Melanoma in situ, superficial spreading type Superficial spreading melanoma, vertical
    [Show full text]
  • View Continuation Patent in PDF Format
    I 1111111111111111 1111111111 lllll lllll lllll 111111111111111 111111111111111111 US010144773B2 c12) United States Patent (IO) Patent No.: US 10,144,773 B2 Cook et al. (45) Date of Patent: *Dec. 4, 2018 (54) METHODS OF USE OF SECRETORY IGA WO 2004000035 Al 12/2003 WO 2009156301 Al 12/2009 (71) Applicant: WISCONSIN ALUMNI RESEARCH WO 2012080306 Al 6/2012 WO 2013087911 Al 6/2013 FOUNDATION, Madison, WI (US) WO 2013132052 Al 9/2013 WO 20140107269 Al 7/2014 (72) Inventors: Mark E. Cook, Madison, WI (US); Jordan Marshall Sand, Madison, WI OTHER PUBLICATIONS (US); Lisa Ann Krugner-Higby, Belleville, WI (US); James Mukasa Hampton et al., J Am Assoc Lab Anim Sci. 2012;51(5):586-93.* Ntambi, Fitchburg, WI (US) Nowland et al., "Guidelines on Treatment of Ulcerative Dermatitis" downloaded Jul. 26, 2018 from wiki.med.umich.edu/display/ (73) Assignee: WISCONSIN ALUMNI RESEARCH ULAMGSOP/Guidelines+on+ Treatment +of+ Ulcerative+ Dermati­ FOUNDATION, Madison, WI (US) tis, 2 pages.* Berneman, et al.; "The Specificity Patterns of Human Immuno­ ( *) Notice: Subject to any disclaimer, the term ofthis globulin G Antibodies in Serum Differ from Those in Autologous patent is extended or adjusted under 35 Secretions"; Infection and Immunity; pp. 4163-4168; (1998). U.S.C. 154(b) by 150 days. Definition of Feed efficiency, found in "Introduction to Animal Science"; Third Edition; W. Stephen Damron, Ed.; Pearson, Pren­ This patent is subject to a terminal dis­ tice Hall; p. 785; 2006. claimer. Karczewski, Jerry; "Animal-Derived Medicines Play a Critical Role in Human Health Care"; Meat+Poultry; Jan. 2017; pp. 16-22; (21) Appl.
    [Show full text]
  • Ulcerative Dermatitis in Mice
    Ulcerative Dermatitis in Mice Background Ulcerative dermatitis (UD) is a common idiopathic non-infectious skin condition in mice that is characterized by hair loss, skin redness and itching that rapidly progresses to excoriation and ulceration of the skin as a result of self-trauma.1 Due to the potential discomfort and pain associated with this condition and its high prevalence, UD is considered one of the most important welfare issues in lab mice.1,2 Etiology & Risk Factors While the exact etiology of UD is still unknown, recent literature suggests it may be a type I hypersensitivity response.3,4 The condition has been associated with various other pathologic processes.5-7 Risk factors for the development of UD include:1 C57BL/6 genetic background Increasing age – median age of onset is approximately 15 months8 Sex – earlier onset and higher prevalence in females9 High-fat diet consumption Changes in humidity Investigators planning studies using C57BL/6-background mice, especially aging studies, should anticipate that UD lesions may develop in approximately 20% of the mice8,10 and may require pharmacologic treatment or euthanasia. Management Early recognition and intervention is key for successfully managing UD cases. Lab personnel who are regularly handling their mice may be in the best position to identify early UD lesions that have a good prognosis for recovery. Report any health concerns to DCM for further evaluation so that we may assess the animal and recommend appropriate treatment(s). When DCM veterinary staff diagnose UD, they will assign a severity score and recommend treatment according to the table below.
    [Show full text]
  • Proceedings Book
    th ANNUAL CONGRESS 26 OF THE ESVD-ECVD 19-21 SEPTEMBER 2013 | VALENCIA SPAIN VALENCIA CONFERENCE CENTRE PROCEEDINGS BOOK THE LONG-TERM PARTNERS OF ESVD/ECVD WWW.ESVD-ECVDCONGRESS.COM Congress Secretariat Alexander Battalaan 7 6221 CA Maastricht, The Netherlands T +31 (0) 43 325 49 08 | F +31 (0) 43 321 43 70 E [email protected] I www.pauwelspco.nl th ANNUAL CONGRESS 26 OF THE ESVD-ECVD 19-21 SEPTEMBER 2013 | VALENCIA SPAIN VALENCIA CONFERENCE CENTRE PROCEEDINGS BOOK THE LONG-TERM PARTNERS OF ESVD/ECVD WWW.ESVD-ECVDCONGRESS.COM 26TH ANNUAL CONGRESS OF THE ESVD-ECVD | 19-21 SEPTEMBER 2013 | VALENCIA SPAIN | VALENCIA CONFERENCE CENTRE WELCOME TO VALENCIA! Dear Friends and colleagues, We are very happy to welcome you to Valencia, “The City of Light and Flowers” for this 26th Annual Congress of the European Society and College of Veterinary Dermatology. As for previous European dermatology congresses, the Scientifi c Organizing Committee has organized two separate lecture tracks: the Continuing Education Program (which is to be simultaneously interpreted from English to Spanish) has lectures on the diagnosis and treatment of the main alopecic and pruritic dermatoses while the Advanced Program was set with high level lectures about the skin barrier, topical therapy, itch and autoimmune skin diseases. As for the 2011 congress, we have reserved a third room for expanded oral and poster short communication theme-based sessions. The Local Organizing Committee chose the city of Valencia because of its luminosity and strategic situation next to the Mediterranean Sea. This location provides all of us, clinicians and scientists alike, with the possibility to expand beyond veterinary dermatology to meet an ancient culture, to be exposed to the sun (hopefully) and to taste the wonderfully famous local gastronomy.
    [Show full text]
  • Antioxidant Therapies for Ulcerative Dermatitis: a Potential Model for Skin Picking Disorder
    RESEARCH ARTICLE Antioxidant Therapies for Ulcerative Dermatitis: A Potential Model for Skin Picking Disorder Nneka M. George1*, Julia Whitaker1, Giovana Vieira2, Jerome T. Geronimo3, Dwight A. Bellinger1, Craig A. Fletcher1, Joseph P. Garner3,4 1 Department of Pathology and Laboratory Medicine, Division of Laboratory Animal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 2 Department of Animal Sciences, Purdue University, West Lafayette, Indiana, United States of America, 3 Department of a11111 Comparative Medicine, Stanford University, Stanford, California, United States of America, 4 Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, United States of America * [email protected] Abstract OPEN ACCESS Skin Picking Disorder affects 4% of the general population, with serious quality of life impacts, Citation: George NM, Whitaker J, Vieira G, Geronimo JT, Bellinger DA, Fletcher CA, et al. (2015) and potentially life threatening complications. Standard psychoactive medications do not Antioxidant Therapies for Ulcerative Dermatitis: A help most patients. Similarly, Mouse Ulcerative Dermatitis (skin lesions caused by excessive Potential Model for Skin Picking Disorder. PLoS ONE abnormal grooming behavior) is very common in widely used inbred strains of mice, and rep- 10(7): e0132092. doi:10.1371/journal.pone.0132092 resents a serious animal welfare issue and cause of mortality. Treatment options for Ulcera- Editor: Michael Bader, Max-Delbrück Center for tive Dermatitis are largely palliative and ineffective. We have proposed mouse Ulcerative Molecular Medicine (MDC), GERMANY Dermatitis as a model for human Skin Picking Disorder based on similar epidemiology, Received: January 16, 2015 behavior, and its comorbidity and mechanistic overlap with hair pulling (trichotillomania).
    [Show full text]